Labcorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.
Increasingly, biomarkers play a key role in therapeutic development programs and have been shown to improve drug approval success rates by nearly 3-fold. Some biomarkers transition to become a companion diagnostic and as such, are a required test for prescribing a specific therapy. In this webinar, we focus on the development journey of a biomarker from early discovery, through clinical development and ultimately to an approved, commercially available companion diagnostic test. We present the example of and best practices discerned from a recently approved companion diagnostic assay which is used to assess the eligibility of patients with urothelial cancer for treatment with the newly approved FGFR kinase inhibitor, BALVERSA™ (erdafitinib).
Covance Chief Scientific Officer Steve Anderson speaks about the importance of partnerships in delivering on the promise of precision medicine.
Press Release: LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced the availability of a newly-approved companion diagnostic by the U.S. Food and Drug Administration (FDA), the therascreen® FGFR mutation assay by RGQ RT-PCR, which is now available for ordering from LabCorp and its Integrated Oncology specialty laboratory.
At ASCO 2019, LabCorp's Senior Director for Molecular Oncology Anjen Chenn, MD Ph.D, speaks about FGFR testing solutions from QIAGEN and how it works. He also answers the question: Why does Day One Lab Readiness matter?
Hilden, Germany, and Germantown, Maryland, April 03, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a master service agreement with LabCorp® (NYSE: LH) to further accelerate the access of cancer patients to QIAGEN’s companion diagnostic products following regulatory approvals of drugs and their associated tests. [...]
At ASCO 2019, Tom Turi speaks about companion diagnostics and the benefits for labs and patients gained from the Day One Lab Readiness program from QIAGEN.
Following earlier LabCorp strategic investment, Mission Bio single cell-sequencing technology will be used by LabCorp to support clinical trials, along with the evaluation of potential applications in clinical diagnostics and companion diagnostics development
LabCorp Chairman and CEO David P. King's Keynote Speech from 14th Annual Personalized Medicine Conference
David P. King keynote highlights from 14th Annual Personalized Medicine Conference at Harvard Medical School
Alliance intended to establish image analysis-enabled companion diagnostics as standard for comprehensive targeted therapies
LabCorp Chief Medical Officer Brian Caveney Speaks about the Economics of Precision Medicine at the Precision Medicine World Conference at Duke University
Collaboration creates global laboratory network for the development and commercialization of companion diagnostics
Immunotherapy has revolutionized the treatment of cancer by harnessing the power of the human immune system to combat the disease. These new therapies help prevent cancer cells from switching off the immune system in an effort to survive, thereby allowing the immune system to detect and destroy cancerous cells. [...]